A risk-based approach for detection of recurrent CIN

Utilizing HPV genotyping and DNA methylation analysis can aid in distinguishing between women requiring re-treatment and those who can be managed conservatively, reducing unnecessary interventions and associated obstetric complications. The incorporation of HPV testing post-treatment has shown to be both safe and cost-effective, enhancing the accuracy of post-treatment surveillance and providing insights in vaccination benefit for treated women. Rebecca Millecamps from Fujirebio discusses the need for effective post-treatment surveillance strategies for women treated for CIN2/3 to detect recurrent lesions and prevent overtreatment, considering the persistent risk of cervical cancer. Additionally, DNA methylation testing is highlighted as a promising approach for detecting recurrent CIN after treatment, particularly for identifying residual lesions in need of re-treatment.